Bionoid Pharma Stock Performance
| BINP Stock | USD 0.11 0.09 45.00% |
The firm shows a Beta (market volatility) of -0.61, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Bionoid Pharma are expected to decrease at a much lower rate. During the bear market, Bionoid Pharma is likely to outperform the market. At this point, Bionoid Pharma has a negative expected return of -0.27%. Please make sure to confirm Bionoid Pharma's variance, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Bionoid Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Weak
Over the last 90 days Bionoid Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Total Cashflows From Investing Activities | -24.2 K |
Bionoid |
Bionoid Pharma Relative Risk vs. Return Landscape
If you would invest 30.00 in Bionoid Pharma on August 29, 2024 and sell it today you would lose (19.00) from holding Bionoid Pharma or give up 63.33% of portfolio value over 90 days. Bionoid Pharma is currently does not generate positive expected returns and assumes 14.6613% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bionoid, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bionoid Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bionoid Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bionoid Pharma, and traders can use it to determine the average amount a Bionoid Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0186
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BINP |
Estimated Market Risk
| 14.66 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bionoid Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bionoid Pharma by adding Bionoid Pharma to a well-diversified portfolio.
Bionoid Pharma Fundamentals Growth
Bionoid Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bionoid Pharma, and Bionoid Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionoid Pink Sheet performance.
| Return On Asset | -1.64 | |||
| Operating Margin | (4.22) % | |||
| Current Valuation | 3.81 M | |||
| Shares Outstanding | 42.28 M | |||
| Price To Sales | 540.76 X | |||
| Revenue | 92.26 K | |||
| EBITDA | (385.71 K) | |||
| Cash And Equivalents | 127 | |||
| Total Debt | 64.5 K | |||
| Book Value Per Share | (29.92) X | |||
| Cash Flow From Operations | (357.62 K) | |||
| Earnings Per Share | (46.27) X | |||
About Bionoid Pharma Performance
Assessing Bionoid Pharma's fundamental ratios provides investors with valuable insights into Bionoid Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bionoid Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Bionoid Pharma Inc. engages in the hemp cultivation business. Bionoid Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Bionoid Pharma performance evaluation
Checking the ongoing alerts about Bionoid Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bionoid Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionoid Pharma generated a negative expected return over the last 90 days | |
| Bionoid Pharma has high historical volatility and very poor performance | |
| Bionoid Pharma has some characteristics of a very speculative penny stock | |
| Bionoid Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Bionoid Pharma currently holds 64.5 K in liabilities. Bionoid Pharma has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bionoid Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bionoid Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionoid Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionoid to invest in growth at high rates of return. When we think about Bionoid Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K. | |
| Bionoid Pharma currently holds about 127 in cash with (357.62 K) of positive cash flow from operations. |
- Analyzing Bionoid Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionoid Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Bionoid Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionoid Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionoid Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionoid Pharma's pink sheet. These opinions can provide insight into Bionoid Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.